再発性多発性硬化症の治療における概念の進化
Giancarlo Comi1, Marta Radaelli1, Per Soelberg Sørensen2
1Department of Neurology and Institute of Experimental Neurology, San Raffaele Hospital, Milan, Italy.
Lancet (London, England)
|November 28, 2016
まとめ
多発性硬化症 (MS) の治療は,早期の介入を必要とする臨床的またはMRI活動の欠如を目指すように進化しました. パーソナライズされた治療戦略は 病気の要因と患者のプロフィールを考慮して 利益を最大化し リスクを最小限に抑えることが重要です
科学分野:
- 神経学
- 免疫学
- 薬理学について
背景:
- 多発性硬化症 (MS) の治療は 過去20年間に大幅に進歩しました
- 治療目標は再発の減少から,完全な疾患寛解 (臨床的またはMRI活動なし) に移行した.
研究 の 目的:
- 現代の多発性硬化症の 治療法の複雑さを強調するためです
- 薬物メカニズムとリスク・ベネフィット・プロファイルを理解することの重要性を強調する.
- 患者の治療戦略を最適化するために神経科医を指導する.
主な方法:
- 多発性硬化症の現在の治療方法のレビュー
- 変化する治療環境と目標の分析
- 病気の活動,病歴,リスク耐性などの治療選択に影響を与える要因を考慮する.
主要な成果:
- 効果的な疾患変異療法が 現在広く利用可能になっています
- MSの炎症期では早期に治療を開始することが重要です.
- パーソナライズされた治療の選択には,病気の予後要因,併発症,および患者特有の考慮事項の慎重な評価が必要です.
結論:
- 多発性硬化症の治療を最適化するには 病気のメカニズムと 患者の個々の要因を 徹底的に理解する必要があります
- 適度でない反応を早期に特定するには,厳密な臨床モニタリングが不可欠です.
- 多発性硬化症の患者に最大限の利益と最小限のリスクを保証するために,治療戦略は適応可能であるべきです.
関連する概念動画
01:20Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
01:28Drug Therapy
361
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
361
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:17Classification of Illness
9.2K
The meaning of illness is individualized to each person who experiences an alteration in health. In contrast, disease is a medical term indicating a pathological change in the structure and function of the body or mind. It is a condition that has specific symptoms and boundaries.
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
9.2K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:25Long-term Potentiation
3.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
3.8K